Champions Oncology Inc. shares surged 8.2% in premarket trade Monday on news of the company’s collaboration with AstraZeneca . The companies plan to develop new Patient-Derived Xenograft (PDX) models — cancer tumors transplanted into mice that are used to study cancer — for their cancer research. These new models will focus on metastatic, previously treated cancers so researchers can better understand mechanisms of resistance, the companies said, “providing a critical platform to optimize drug development in these settings.” Those two areas of cancer research are a “surprisingly underserved space,” said AstraZeneca Vice President and Head of Oncology Steve Fawell. AstraZeneca shares declined 0.5% in premarket trade. Champions shares have surged 29.2% over the last three months to $3.19 and AstraZeneca shares have dropped 14.1%, compared with a 1.8% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News